Filip K Knop

List of Publications by Year
in descending order

461 papers	18,344 citations	13099 68 h-index	21540 114 g-index
496 all docs	496 docs citations	496 times ranked	18094 citing authors

#	Article	IF	Citations
1	Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ: British Medical Journal, 2012, 344, d7771-d7771.	2.3	731
2	Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. Cell Metabolism, 2017, 26, 611-619.e6.	16.2	689
3	Recovery of gut microbiota of healthy adults following antibiotic exposure. Nature Microbiology, 2018, 3, 1255-1265.	13.3	483
4	Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. Journal of Hepatology, 2014, 60, 824-831.	3.7	475
5	Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia, 2009, 52, 199-207.	6.3	351
6	Glucagon-like peptide 1 in health and disease. Nature Reviews Endocrinology, 2018, 14, 390-403.	9.6	304
7	Reduced Incretin Effect in Type 2 Diabetes. Diabetes, 2007, 56, 1951-1959.	0.6	297
8	Glucose-Dependent Insulinotropic Polypeptide. Diabetes, 2011, 60, 3103-3109.	0.6	265
9	2-Oleoyl Glycerol Is a GPR119 Agonist and Signals GLP-1 Release in Humans. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1409-E1417.	3.6	238
10	Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes. Diabetes Care, 2011, 34, S251-S257.	8.6	233
11	The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action. Diabetes, 2010, 59, 1765-1770.	0.6	230
12	Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia, 2013, 56, 965-972.	6.3	199
13	The Pathophysiology of Diabetes Involves a Defective Amplification of the Late-Phase Insulin Response to Glucose by Glucose-Dependent Insulinotropic Polypeptideâ€"Regardless of Etiology and Phenotype. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4897-4903.	3.6	197
14	Impaired Regulation of the Incretin Effect in Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 737-745.	3.6	190
15	Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0166125.	2.5	188
16	Plasma proteome profiling discovers novel proteins associated with nonâ€alcoholic fatty liver disease. Molecular Systems Biology, 2019, 15, e8793.	7.2	176
17	Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial) Tj ETQq1 1 0.784314 rgBT /Over	2.7	171
18	Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia, 2007, 50, 797-805.	6.3	165

#	Article	IF	Citations
19	Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals. American Journal of Physiology - Renal Physiology, 2019, 316, G462-G472.	3.4	162
20	Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?. Diabetologia, 2014, 57, 1919-1926.	6.3	156
21	Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. Diabetes, Obesity and Metabolism, 2012, 14, 500-510.	4.4	153
22	Increased Postprandial GIP and Glucagon Responses, But Unaltered GLP-1 Response after Intervention with Steroid Hormone, Relative Physical Inactivity, And High-Calorie Diet in Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 447-453.	3.6	152
23	The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. American Journal of Physiology - Endocrinology and Metabolism, 2011, 300, E1038-E1046.	3.5	148
24	Glucagon and Amino Acids Are Linked in a Mutual Feedback Cycle: The Liverâ€"Î±-Cell Axis. Diabetes, 2017, 66, 235-240.	0.6	144
25	The Nkx6.1 homeodomain transcription factor suppresses glucagon expression and regulates glucose-stimulated insulin secretion in islet beta cells. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 7297-7302.	7.1	142
26	The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. American Journal of Physiology - Renal Physiology, 2013, 304, G1117-G1127.	3.4	138
27	Evidence of Extrapancreatic Glucagon Secretion in Man. Diabetes, 2016, 65, 585-597.	0.6	136
28	Regulation of glucagon secretion by incretins. Diabetes, Obesity and Metabolism, 2011, 13, 89-94.	4.4	132
29	Self-Expanding Metal Stents for Colonic Obstruction: Experiences From 104 Procedures in a Single Center. Diseases of the Colon and Rectum, 2004, 47, 444-450.	1.3	130
30	Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2016, 4, 221-232.	11.4	127
31	Continuous glucose monitoring in pregnant women with type 1 diabetes: an observational cohort study of 186 pregnancies. Diabetologia, 2019, 62, 1143-1153.	6.3	127
32	Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes. Diabetes Care, 2013, 36, 3346-3352.	8.6	125
33	Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects. World Journal of Hepatology, 2019, 11, 138-149.	2.0	122
34	Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: Differences and similarities. European Journal of Internal Medicine, 2014, 25, 407-414.	2.2	120
35	Use of Antibiotics and Risk of Type 2 Diabetes: A Population-Based Case-Control Study. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3633-3640.	3.6	118
36	Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals. Diabetes, 2019, 68, 906-917.	0.6	118

#	Article	IF	Citations
37	Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans. European Journal of Endocrinology, 2014, 170, 529-538.	3.7	116
38	Glucagon antagonism as a potential therapeutic target in type 2 diabetes. Diabetes, Obesity and Metabolism, 2011, 13, 965-971.	4.4	114
39	Glucagon Receptor Signaling and Glucagon Resistance. International Journal of Molecular Sciences, 2019, 20, 3314.	4.1	113
40	Glucagon Receptor Signaling and Lipid Metabolism. Frontiers in Physiology, 2019, 10, 413.	2.8	112
41	The Liverâ€"Î±-Cell Axis and Type 2 Diabetes. Endocrine Reviews, 2019, 40, 1353-1366.	20.1	110
42	Effect of the <scp>EndoBarrier G</scp>astrointestinal <scp>L</scp>iner on obesity and type 2 diabetes: a systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2016, 18, 300-305.	4.4	107
43	Enteroendocrine K and L cells in healthy and type 2 diabetic individuals. Diabetologia, 2018, 61, 284-294.	6.3	107
44	Clinical relevance of the bile acid receptor TGR5 in metabolism. Lancet Diabetes and Endocrinology,the, 2017, 5, 224-233.	11.4	105
45	Twelve weeks treatment with the DPPâ€4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and nonâ€glucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2010, 12, 323-333.	4.4	104
46	Glucose-Dependent Insulinotropic Polypeptide Inhibits Bone Resorption in Humans. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2325-E2329.	3.6	104
47	The biology of glucagon and the consequences of hyperglucagonemia. Biomarkers in Medicine, 2016, 10, 1141-1151.	1.4	102
48	Postprandial Plasma Concentrations of Individual Bile Acids and FGF-19 in Patients With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3002-3009.	3.6	100
49	Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. Annals of the Rheumatic Diseases, 2017, 76, 1870-1882.	0.9	98
50	Glucagon and Type 2 Diabetes: the Return of the Alpha Cell. Current Diabetes Reports, 2014, 14, 555.	4.2	96
51	Glucose-Lowering Effects and Low Risk of Hypoglycemia in Patients With Maturity-Onset Diabetes of the Young When Treated With a GLP-1 Receptor Agonist: A Double-Blind, Randomized, Crossover Trial. Diabetes Care, 2014, 37, 1797-1805.	8.6	94
52	Effect of Roux-en-Y gastric bypass on the distribution and hormone expression of small-intestinal enteroendocrine cells in obese patients with type 2 diabetes. Diabetologia, 2015, 58, 2254-2258.	6.3	94
53	The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes. Mayo Clinic Proceedings, 2018, 93, 217-239.	3.0	94
54	Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E324-E330.	3.5	92

#	Article	IF	Citations
55	Reduced Glucose Tolerance and Insulin Resistance Induced by Steroid Treatment, Relative Physical Inactivity, and High-Calorie Diet Impairs the Incretin Effect in Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3309-3317.	3.6	92
56	Glucagonâ€like peptideâ€1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 906-908.	4.4	90
57	Preserved Inhibitory Potency of GLP-1 on Glucagon Secretion in Type 2 Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4679-4687.	3.6	89
58	Speciesâ€specific action of (Pro3)GIP â€“ a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors. British Journal of Pharmacology, 2016, 173, 27-38.	5.4	86
59	Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes. JCI Insight, 2018, 3, .	5.0	86
60	Specificity and sensitivity of commercially available assays for glucagonâ€like peptideâ€1 (<scp>GLP</scp>â€1): implications for <scp>GLP</scp>â€1 measurements in clinical studies. Diabetes, Obesity and Metabolism, 2014, 16, 1155-1164.	4.4	85
61	Effect of Antibiotics on Gut Microbiota, Gut Hormones and Glucose Metabolism. PLoS ONE, 2015, 10, e0142352.	2.5	85
62	Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes. Diabetologia, 2008, 51, 632-640.	6.3	82
63	Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study. Diabetologia, 2019, 62, 665-675.	6.3	81
64	Glucose-dependent Insulinotropic Polypeptide: Blood Glucose Stabilizing Effects in Patients With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E418-E426.	3.6	79
65	Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling?. Diabetologia, 2009, 52, 2270-2276.	6.3	77
66	Echocardiographic abnormalities and predictors of mortality in hospitalized COVIDâ€19 patients: the ECHOVIDâ€19 study. ESC Heart Failure, 2020, 7, 4189-4197.	3.1	77
67	Evidence of a liverâ€“alpha cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids. Diabetologia, 2018, 61, 671-680.	6.3	76
68	Nâ€terminally and Câ€terminally truncated forms of glucoseâ€dependent insulinotropic polypeptide are highâ€affinity competitive antagonists of the human GIP receptor. British Journal of Pharmacology, 2016, 173, 826-838.	5.4	72
69	Bile acid sequestrants for glycemic control in patients with type 2 diabetes: A systematic review with meta-analysis of randomized controlled trials. Journal of Diabetes and Its Complications, 2017, 31, 918-927.	2.3	72
70	Palaeolithic diet decreases fasting plasma leptin concentrations more than a diabetes diet in patients with type 2 diabetes: a randomised cross-over trial. Cardiovascular Diabetology, 2016, 15, 80.	6.8	71
71	Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagonâ€like peptideâ€1 secretion. Diabetes, Obesity and Metabolism, 2016, 18, 571-580.	4.4	71
72	Lixisenatide for type 2 diabetes mellitus. Expert Opinion on Investigational Drugs, 2011, 20, 549-557.	4.1	70

#	Article	IF	Citations
73	Mechanism of Metabolic Advantages After Bariatric Surgery. Diabetes Care, 2013, 36, S287-S291.	8.6	70
74	Incidence and Prognosis of Psoriasis and Psoriatic Arthritis in Patients Undergoing Bariatric Surgery. JAMA Surgery, 2017, 152, 344.	4.3	69
75	Glucagonâ€like peptideâ€1 receptor agonists for antipsychoticâ€associated cardioâ€metabolic risk factors: A systematic review and individual participant data metaâ€analysis. Diabetes, Obesity and Metabolism, 2019, 21, 293-302.	4.4	69
76	Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes. American Journal of Physiology - Endocrinology and Metabolism, 2010, 298, E832-E837.	3.5	67
77	Genetic variation in the two-pore domain potassium channel, TASK-1, may contribute to an atrial substrate for arrhythmogenesis. Journal of Molecular and Cellular Cardiology, 2014, 67, 69-76.	1.9	66
78	GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study. Diabetologia, 2018, 61, 413-423.	6.3	66
79	Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis. Molecular Metabolism, 2020, 42, 101080.	6.5	66
80	Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4541-4552.	3.6	65
81	Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD. Frontiers in Endocrinology, 2018, 9, 649.	3.5	65
82	Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 288-294.	3.6	64
83	MECHANISMS IN ENDOCRINOLOGY: Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion. European Journal of Endocrinology, 2014, 171, R47-R65.	3.7	62
84	Patients with psoriasis are insulin resistant. Journal of the American Academy of Dermatology, 2015, 72, 599-605.	1.2	62
85	Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial. Diabetes Care, 2016, 39, 206-213.	8.6	62
86	Effect of antibiotics on gut microbiota, glucose metabolism and body weight regulation: a review of the literature. Diabetes, Obesity and Metabolism, 2016, 18, 444-453.	4.4	62
87	FGF21, a liver hormone that inhibits alcohol intake in mice, increases in human circulation after acute alcohol ingestion and sustained binge drinking at Oktoberfest. Molecular Metabolism, 2018, 11, 96-103.	6.5	62
88	Impaired Incretin-Induced Amplification of Insulin Secretion after Glucose Homeostatic Dysregulation in Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1363-1370.	3.6	61
89	Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes. American Journal of Physiology - Renal Physiology, 2018, 314, G91-G96.	3.4	61
90	Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. Peptides, 2020, 125, 170183.	2.4	61

#	Article	IF	Citations
91	Glucose-Dependent Insulinotropic Polypeptide Augments Glucagon Responses to Hypoglycemia in Type 1 Diabetes. Diabetes, 2015, 64, 72-78.	0.6	60
92	Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia. Journal of Internal Medicine, 2016, 279, 485-493.	6.0	58
93	Exenatide: pharmacokinetics, clinical use, and future directions. Expert Opinion on Pharmacotherapy, 2017, 18, 555-571.	1.8	58
94	Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects. Diabetic Medicine, 2013, 30, 1214-1218.	2.3	57
95	Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1. European Journal of Endocrinology, 2014, 171, 407-419.	3.7	56
96	Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals. Diabetologia, 2014, 57, 1720-1725.	6.3	56
97	GLP-1 and Amylin in the Treatment of Obesity. Current Diabetes Reports, 2016, 16, 1.	4.2	56
98	Supportive and non-supportive interactions in families with a type 2 diabetes patient: an integrative review. Diabetology and Metabolic Syndrome, 2017, 9, 57.	2.7	56
99	Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents. Peptides, 2018, 100, 173-181.	2.4	56
100	The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance. Regulatory Peptides, 2007, 144, 123-130.	1.9	55
101	Nonalcoholic Fatty Liver Disease Is Prevalent in Women With Prior Gestational Diabetes Mellitus and Independently Associated With Insulin Resistance and Waist Circumference. Diabetes Care, 2017, 40, 109-116.	8.6	54
102	L-Cell Differentiation Is Induced by Bile Acids Through GPBAR1 and Paracrine GLP-1 and Serotonin Signaling. Diabetes, 2020, 69, 614-623.	0.6	54
103	Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes?. American Journal of Physiology - Endocrinology and Metabolism, 2010, 299, E10-E13.	3.5	53
104	Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma. EBioMedicine, 2016, 7, 112-120.	6.1	53
105	Effect of <scp>GLP</scp>â€1 receptor agonist treatment on body weight in obese antipsychoticâ€treated patients with schizophrenia: <scp>a</scp> randomized, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2017, 19, 162-171.	4.4	53
106	Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes. BMJ Open, 2014, 4, e005325.	1.9	52
107	Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty. European Journal of Endocrinology, 2013, 169, 187-201.	3.7	51
108	Involvement of glucagonâ€like peptideâ€1 in the glucoseâ€lowering effect of metformin. Diabetes, Obesity and Metabolism, 2016, 18, 955-961.	4.4	50

#	Article	IF	Citations
109	Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic Steatosis. Diabetes, 2020, 69, 1090-1099.	0.6	50
110	GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 17-29.	3.3	49
111	The Alpha-Cell as Target for Type 2 Diabetes Therapy. Review of Diabetic Studies, 2011, 8, 369-381.	1.3	49
112	K_{ATP}Channel Closure Ameliorates the Impaired Insulinotropic Effect of Glucose-Dependent Insulinotropic Polypeptide in Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 603-608.	3.6	48
113	Diabetes and obesity treatment based on dual incretin receptor activation: â€˜twincretinsâ€™. Diabetes, Obesity and Metabolism, 2016, 18, 847-854.	4.4	47
114	The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretionâ€"A Review. International Journal of Molecular Sciences, 2019, 20, 4092.	4.1	47
115	Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis. BMC Gastroenterology, 2020, 20, 210.	2.0	47
116	GLP-1 Restores Altered Insulin and Glucagon Secretion in Posttransplantation Diabetes. Diabetes Care, 2016, 39, 617-624.	8.6	46
117	Four weeks of nearâ€normalization of blood glucose has no effect on postprandial GLPâ€1 and GIP secretion, but augments pancreatic Bâ€cell responsiveness to a meal in patients with TypeÂ2 diabetes. Diabetic Medicine, 2008, 25, 1268-1275.	2.3	45
118	Cephalic phase secretion of insulin and other enteropancreatic hormones in humans. American Journal of Physiology - Renal Physiology, 2016, 310, G43-G51.	3.4	45
119	Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients. American Journal of Physiology - Renal Physiology, 2013, 304, G413-G419.	3.4	43
120	Bile Acid Sequestrants: Glucose-Lowering Mechanisms and Efficacy in Type 2 Diabetes. Current Diabetes Reports, 2014, 14, 482.	4.2	43
121	Incretin Effect and Glucagon Responses to Oral and Intravenous Glucose in Patients With Maturity-Onset Diabetes of the Young–Type 2 and Type 3. Diabetes, 2014, 63, 2838-2844.	0.6	43
122	Hemodynamic Effects of Glucagon: A Literature Review. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1804-1812.	3.6	43
123	Nonâ€alcoholic fatty liver disease alters expression of genes governing hepatic nitrogen conversion. Liver International, 2019, 39, 2094-2101.	3.9	43
124	Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide?. Current Diabetes Reports, 2010, 10, 124-132.	4.2	42
125	Current evidence for a role of GLPâ€1 in Rouxâ€enâ€Y gastric bypassâ€induced remission of type 2 diabetes. Diabetes, Obesity and Metabolism, 2012, 14, 291-298.	4.4	41
126	Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes. International Journal of Obesity, 2015, 39, 1651-1654.	3.4	41

#	Article	IF	Citations
127	Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2953-2960.	3.6	41
128	Incretin-Based Therapy of Type 2 Diabetes Mellitus. Current Protein and Peptide Science, 2009, 10, 46-55.	1.4	40
129	No Hypoglycemia After Subcutaneous Administration of Glucagon-Like Peptide-1 in Lean Type 2 Diabetic Patients and in Patients With Diabetes Secondary to Chronic Pancreatitis. Diabetes Care, 2003, 26, 2581-2587.	8.6	39
130	Lack of effect of the glucagonâ€like peptideâ€1 receptor agonist liraglutide on psoriasis in glucoseâ€tolerant patients â€“ a randomized placeboâ€controlled trial. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 555-559.	2.4	39
131	Effects of glucagonâ€like peptideâ€1 receptor agonists on cardiovascular risk factors: A narrative review of headâ€toâ€head comparisons. Diabetes, Obesity and Metabolism, 2018, 20, 508-519.	4.4	39
132	Metabolic profile in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. International Journal of Bipolar Disorders, 2019, 7, 8.	2.2	39
133	Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 313-324.	11.4	39
134	Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide. Acta Diabetologica, 2014, 51, 147-150.	2.5	38
135	EJE PRIZE 2018: A gut feeling about glucagon. European Journal of Endocrinology, 2018, 178, R267-R280.	3.7	38
136	No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes. Diabetes Care, 2020, 43, 588-596.	8.6	38
137	Mechanisms of the Incretin Effect in Subjects with Normal Glucose Tolerance and Patients with Type 2 Diabetes. PLoS ONE, 2013, 8, e73154.	2.5	38
138	Reduced postprandial <scp>GLP</scp>â€1 responses in women with gestational diabetes mellitus. Diabetes, Obesity and Metabolism, 2013, 15, 713-720.	4.4	37
139	GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e725-e738.	3.6	37
140	Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists. International Journal of Clinical Practice, 2009, 63, 1154-1160.	1.7	36
141	No cognitiveâ€enhancing effect of <scp>GLP</scp>â€1 receptor agonism in antipsychoticâ€treated, obese patients with schizophrenia. Acta Psychiatrica Scandinavica, 2017, 136, 52-62.	4.5	36
142	Nearâ€normalization of glycaemic control with glucagonâ€like peptideâ€1 receptor agonist treatment combined with exercise in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 172-180.	4.4	36
143	Influenza Vaccination Is Associated With Reduced Cardiovascular Mortality in Adults With Diabetes: A Nationwide Cohort Study. Diabetes Care, 2020, 43, 2226-2233.	8.6	36
144	Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodiumâ€“Glucose Cotransporter 2 Inhibitor Treatment. Basic and Clinical Pharmacology and Toxicology, 2016, 118, 168-170.	2.5	35

#	Article	IF	Citations
145	Use of antibiotics in childhood and risk of Type 1 diabetes: a populationâ€based caseâ€“control study. Diabetic Medicine, 2017, 34, 272-277.	2.3	35
146	Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 0, Volume 3, 155-163.	2.4	34
147	Gastric bypass surgery: Improving psoriasis through a GLP-1-dependent mechanism?. Medical Hypotheses, 2011, 77, 1098-1101.	1.5	34
148	Lipid and liver abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 670-676.	2.6	34
149	Adult atopic dermatitis and the risk of type 2 diabetes. Journal of Allergy and Clinical Immunology, 2017, 139, 1057-1059.	2.9	34
150	Investigating Intestinal Glucagon After Roux-en-Y Gastric Bypass Surgery. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6403-6416.	3.6	34
151	Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion. Journal of Diabetes Research, 2016, 2016, 1-5.	2.3	33
152	The bile acidâ€sequestering resin sevelamer eliminates the acute <scp>GLP</scp>â€1 stimulatory effect of endogenously released bile acids in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 362-369.	4.4	33
153	Do the Actions of Glucagon-Like Peptide-1 on Gastric Emptying, Appetite, and Food Intake Involve Release of Amylin in Humans?. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2367-2375.	3.6	31
154	Gastric Emptying of Orally Administered Glucose Solutions and Incretin Hormone Responses Are Unaffected by Laparoscopic Adjustable Gastric Banding. Obesity Surgery, 2011, 21, 625-632.	2.1	31
155	Elimination and Degradation of Glucagon-like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide in Patients with End-Stage Renal Disease. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2457-2466.	3.6	31
156	Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial. European Respiratory Journal, 2022, 59, 2100752.	6.7	31
157	The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma. EBioMedicine, 2021, 73, 103661.	6.1	31
158	Cardiovascular safety and benefits of GLP-1 receptor agonists. Expert Opinion on Drug Safety, 2017, 16, 351-363.	2.4	30
159	FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit. Cell Metabolism, 2022, 34, 317-328.e6.	16.2	30
160	Glucagon suppression during OGTT worsens while suppression during IVGTT sustains alongside development of glucose intolerance in patients with chronic pancreatitis. Regulatory Peptides, 2010, 164, 144-150.	1.9	29
161	Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease. Kidney International, 2013, 83, 915-923.	5.2	29
162	Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production. Cell Reports, 2017, 21, 1452-1460.	6.4	28

#	Article	IF	Citations
163	Effects of liraglutide on gallbladder emptying: A randomized, placeboâ€controlled trial in adults with overweight or obesity. Diabetes, Obesity and Metabolism, 2018, 20, 2557-2564.	4.4	28
164	Association Between Topical Corticosteroid Use and Type 2 Diabetes in Two European Population-Based Adult Cohorts. Diabetes Care, 2019, 42, 1095-1103.	8.6	28
165	Antidiabetes Agents and Incident Depression: A Nationwide Population-Based Study. Diabetes Care, 2020, 43, 3050-3060.	8.6	28
166	Alpha- and beta-cell abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes. Acta Diabetologica, 2014, 51, 567-575.	2.5	27
167	Single-Dose Metformin Enhances Bile Acidâ€"Induced Glucagon-Like Peptide-1 Secretion in Patients With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4153-4162.	3.6	27
168	Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease. Peptides, 2020, 125, 170174.	2.4	27
169	An overview of obesity mechanisms in humans: Endocrine regulation of food intake, eating behaviour and common determinants of body weight. Diabetes, Obesity and Metabolism, 2021, 23, 17-35.	4.4	27
170	A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes. Drugs, 2021, 81, 1003-1030.	10.9	27
171	Effect of exercise combined with glucagonâ€like peptideâ€1 receptor agonist treatment on cardiac function: <scp>A</scp> randomized doubleâ€blind placeboâ€controlled clinical trial. Diabetes, Obesity and Metabolism, 2017, 19, 1040-1044.	4.4	26
172	Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs: the Investigational Drugs Journal, 2009, 12, 503-13.	0.7	26
173	The Liverâ€"Î±-Cell Axis in Health and in Disease. Diabetes, 2022, 71, 1852-1861.	0.6	26
174	Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques. Experimental Dermatology, 2013, 22, 150-152.	2.9	25
175	The impact of dipeptidyl peptidase 4 inhibition on incretin effect, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy subjects. European Journal of Endocrinology, 2014, 171, 353-362.	3.7	25
176	N -acyl taurines are endogenous lipid messengers that improve glucose homeostasis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 24770-24778.	7.1	25
177	GIP and the gut-bone axis â€" Physiological, pathophysiological and potential therapeutic implications. Peptides, 2020, 125, 170197.	2.4	25
178	The role of endogenous GIP and GLP-1 in postprandial bone homeostasis. Bone, 2020, 140, 115553.	2.9	25
179	Hypoglycaemia and cardiac arrhythmias in diabetes. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201882091180.	3.2	25
180	Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat. Frontiers in Endocrinology, 2020, 11, 617400.	3.5	25

#	Article	IF	Citations
181	Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits. BMC Medicine, 2012, 10, 92.	5.5	24
182	Incretin and pancreatic hormone secretion in Caucasian nonâ€diabetic carriers of the <scp>TCF7L2</scp> rs7903146 risk T allele. Diabetes, Obesity and Metabolism, 2013, 15, 91-95.	4.4	24
183	Decreased plasma chemerin levels in women with gestational diabetes mellitus. Diabetic Medicine, 2014, 31, 936-940.	2.3	24
184	Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes â€“ focus on pancreatitis and pancreas cancer. Expert Opinion on Drug Safety, 2015, 14, 171-180.	2.4	24
185	Involvement of steatosis-induced glucagon resistance in hyperglucagonaemia. Medical Hypotheses, 2016, 86, 100-103.	1.5	24
186	Cholecystokinin-Induced Gallbladder Emptying and Metformin Elicit Additive Glucagon-Like Peptide-1 Responses. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2076-2083.	3.6	24
187	The impact of <scp>EndoBarrier</scp> gastrointestinal liner in obese patients with normal glucose tolerance and in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 189-199.	4.4	24
188	Pregnancy loss is associated with type 2 diabetes: a nationwide caseâ€“control study. Diabetologia, 2020, 63, 1521-1529.	6.3	24
189	Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial. American Journal of Clinical Nutrition, 2021, 113, 314-323.	4.7	24
190	The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus. Expert Opinion on Drug Discovery, 2014, 9, 1223-1251.	5.0	23
191	Impaired incretin effect is an early sign of glucose dysmetabolism in nondiabetic patients with psoriasis. Journal of Internal Medicine, 2015, 278, 660-670.	6.0	22
192	The role of efferent cholinergic transmission for the insulinotropic and glucagonostatic effects of GLP-1. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2015, 309, R544-R551.	1.8	22
193	Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control Subjects. Metabolic Syndrome and Related Disorders, 2018, 16, 530-536.	1.3	22
194	Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA). Diabetes Care, 2020, 43, 2025-2033.	8.6	22
195	Identification and Metabolic Profiling of a Novel Human Gut-derived LEAP2 Fragment. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e966-e981.	3.6	22
196	The spectrum of antidiabetic actions of GLP-1 in patients with diabetes. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 453-462.	4.7	21
197	Emerging GLP-1 receptor agonists. Expert Opinion on Emerging Drugs, 2011, 16, 607-618.	2.4	21
198	Postpartum reversibility of impaired incretin effect in gestational diabetes mellitus. Regulatory Peptides, 2013, 186, 104-107.	1.9	21

#	Article	IF	Citations
199	Sustained Weight Loss After Treatment With a Glucagon-Like Peptide-1 Receptor Agonist in an Obese Patient With Schizophrenia and Type 2 Diabetes. American Journal of Psychiatry, 2013, 170, 681-682.	7.2	21
200	Glucoseâ€lowering effects and mechanisms of the bile acidâ€sequestering resin sevelamer. Diabetes, Obesity and Metabolism, 2018, 20, 1623-1631.	4.4	21
201	Effects of endogenous GIP in patients with type 2 diabetes. European Journal of Endocrinology, 2021, 185, 33-45.	3.7	21
202	LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men. Cell Reports Medicine, 2022, 3, 100582.	6.5	21
203	Incretin-Based Therapy and Type 2 Diabetes. Vitamins and Hormones, 2010, 84, 389-413.	1.7	20
204	Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonistâ€"protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol. BMJ Open, 2014, 4, e004158.	1.9	20
205	Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2016, 64, 908-915.	3.7	20
206	GIPâ€™s effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3â€"30)NH2. Bone, 2020, 130, 115079.	2.9	20
207	Arginine-vasopressin mediates counter-regulatory glucagon release and is diminished in type 1 diabetes. ELife, 2021, 10, .	6.0	20
208	Long-Acting GLP-1 Analogs for the Treatment of Type 2 DiabetesÂMellitus. BioDrugs, 2008, 22, 251-257.	4.6	19
209	Effect of the EndoBarrier Gastrointestinal Liner on obesity and type 2 diabetes: protocol for systematic review and meta-analysis of clinical studies. BMJ Open, 2013, 3, e003417.	1.9	19
210	Use of inhaled corticosteroids and the risk of developing type 2 diabetes in patients with chronic obstructive pulmonary disease. Diabetes, Obesity and Metabolism, 2020, 22, 1348-1356.	4.4	19
211	Glucometabolic Hormones and Cardiovascular Risk Markers in Antipsychotic-Treated Patients. Journal of Clinical Psychiatry, 2014, 75, e899-e905.	2.2	19
212	Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes. Regulatory Peptides, 2010, 163, 96-101.	1.9	18
213	Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide. Clinical Pharmacokinetics, 2017, 56, 719-731.	3.5	18
214	Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?. Current Diabetes Reports, 2017, 17, 128.	4.2	18
215	Bone Turnover Markers in Patients With Nonalcoholic Fatty Liver Disease and/or Type 2 Diabetes During Oral Glucose and Isoglycemic Intravenous Glucose. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2042-2049.	3.6	18
216	GIPâ€™s involvement in the pathophysiology of type 2 diabetes. Peptides, 2020, 125, 170178.	2.4	18

#	Article	IF	Citations
217	Differential time responses in inflammatory and oxidative stress markers after a marathon: An observational study. Journal of Sports Sciences, 2020, 38, 2080-2091.	2.0	18
218	Lixisenatide for the treatment of type 2 diabetes. Drugs of Today, 2013, 49, 537.	1.1	18
219	Cardiovascular biomarkers in clinical studies of type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 1350-1360.	4.4	17
220	Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. Scandinavian Journal of Gastroenterology, 2018, 53, 1429-1432.	1.5	17
221	Glucose metabolism in patients with psoriasis. British Journal of Dermatology, 2019, 180, 264-271.	1.5	17
222	How glucagon-like peptide 1 receptor agonists work. Endocrine Connections, 2021, 10, R200-R212.	1.9	17
223	Understanding the place for <scp>GLPâ€1RA</scp> therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection. Diabetes, Obesity and Metabolism, 2021, 23, 40-52.	4.4	17
224	Associations of hypoglycemia, glycemic variability and risk of cardiac arrhythmias in insulin-treated patients with type 2 diabetes: a prospective, observational study. Cardiovascular Diabetology, 2021, 20, 241.	6.8	17
225	Effects of sitagliptin on counterâ€regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized doubleâ€blind placeboâ€controlled crossover study. Diabetes, Obesity and Metabolism, 2015, 17, 546-553.	4.4	16
226	Clearance of glucoregulatory peptide hormones during haemodialysis and haemodiafiltration in non-diabetic end-stage renal disease patients. Nephrology Dialysis Transplantation, 2015, 30, 513-520.	0.7	16
227	Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes. Expert Opinion on Drug Safety, 2017, 16, 387-396.	2.4	16
228	Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 734-738.	4.4	16
229	Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 1123-1129.	2.6	16
230	Differences Between Randomized Clinical Trial Patients and Real-World Initiators of the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide. Diabetes Care, 2018, 41, e133-e135.	8.6	16
231	New Avenues in the Regulation of Gallbladder Motilityâ€"Implications for the Use of Glucagon-Like Peptideâ€"Derived Drugs. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2463-2472.	3.6	16
232	Remission of Bile Acid Malabsorption Symptoms Following Treatment With the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide. Gastroenterology, 2019, 157, 569-571.	1.3	16
233	Influence of gastrointestinal factors on glucose metabolism in patients with cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1522-1528.	2.8	15
234	Pancreatic polypeptide responses to isoglycemic oral and intravenous glucose in humans with and without intact vagal innervation. Peptides, 2015, 71, 229-231.	2.4	15

#	Article	IF	Citations
235	A comprehensive compartmental model of blood glucose regulation for healthy and type 2 diabetic subjects. Medical and Biological Engineering and Computing, 2016, 54, 1383-1398.	2.8	15
236	Guanylin and uroguanylin mRNA expression is increased following Roux-en-Y gastric bypass, but guanylins do not play a significant role in body weight regulation and glycemic control. Peptides, 2018, 101, 32-43.	2.4	15
237	Adaptive changes in pancreas post Rouxâ€enâ€Y gastric bypass induced weight loss. Diabetes/Metabolism Research and Reviews, 2018, 34, e3025.	4.0	15
238	Patient Assessment of Family Function, Glycemic Control and Quality of Life in Adult Patients With Type 2 Diabetes and Incipient Complications. Canadian Journal of Diabetes, 2019, 43, 193-200.	0.8	15
239	Highâ€Dose Glucagon Has Hemodynamic Effects Regardless of Cardiac Betaâ€Adrenoceptor Blockade: A Randomized Clinical Trial. Journal of the American Heart Association, 2020, 9, e016828.	3.7	15
240	The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes. European Journal of Endocrinology, 2021, 184, 383-394.	3.7	15
241	Exendin(9â€39)<scp>NH₂</scp>: Recommendations for clinical use based on a systematic literature review. Diabetes, Obesity and Metabolism, 2021, 23, 2419-2436.	4.4	15
242	Hepatic microbiome in healthy lean and obese humans. JHEP Reports, 2021, 3, 100299.	4.9	15
243	Prediabetes Defined by First Measured HbA1c Predicts Higher Cardiovascular Risk Compared With HbA1c in the Diabetes Range: A Cohort Study of Nationwide Registries. Diabetes Care, 2021, 44, 2767-2774.	8.6	15
244	Small-Bowel Hemangiosarcoma and Capsule Endoscopy. Endoscopy, 2003, 35, 637-637.	1.8	14
245	Increased Levels of YKL-40 and Interleukin 6 in Patients With Chronic Pancreatitis and Secondary Diabetes. Pancreas, 2012, 41, 1316-1318.	1.1	14
246	Postprandial responses of incretin and pancreatic hormones in non-diabetic patients with end-stage renal disease. Nephrology Dialysis Transplantation, 2014, 29, 119-127.	0.7	14
247	Semimechanistic model describing gastric emptying and glucose absorption in healthy subjects and patients with type 2 diabetes. Journal of Clinical Pharmacology, 2016, 56, 340-348.	2.0	14
248	Mechanismâ€Based Modeling of Gastric Emptying Rate and Gallbladder Emptying in Response to Caloric Intake. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 692-700.	2.5	14
249	Risk stratification by endocrinologists of patients with type 2 diabetes in a Danish specialised outpatient clinic: a cross-sectional study. BMC Health Services Research, 2016, 16, 124.	2.2	14
250	Women with prior gestational diabetes mellitus and prediabetes are characterised by a decreased incretin effect. Diabetologia, 2017, 60, 1344-1353.	6.3	14
251	Evidence connecting old, new and neglected glucoseâ€lowering drugs to bile acidâ€induced <scp>GLP</scp>â€1 secretion: <scp>A</scp> review. Diabetes, Obesity and Metabolism, 2017, 19, 1214-1222.	4.4	14
252	Ghrelin secretion in humans â€“ a role for the vagus nerve?. Neurogastroenterology and Motility, 2018, 30, e13295.	3.0	14

#	Article	IF	Citations
253	One Yearâ€™s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. Journal of Clinical Medicine, 2020, 9, 3213.	2.4	14
254	GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1Î± Mutation Carriers. Diabetes, 2020, 69, 1989-2002.	0.6	14
255	Doseâ€dependent efficacy of the glucoseâ€dependent insulinotropic polypeptide (<scp>GIP)</scp> receptor antagonist <scp>GIP</scp>(3â€30)<scp>NH₂</scp> on <scp>GIP</scp> actions in humans. Diabetes, Obesity and Metabolism, 2021, 23, 68-74.	4.4	14
256	Worry vs. knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on metformin and/or sulphonylurea. Current Medical Research and Opinion, 2012, 28, 731-736.	1.9	13
257	Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1493-1503.	3.3	13
258	A sandwich ELISA for measurement of the primary glucagon-like peptide-1 metabolite. American Journal of Physiology - Endocrinology and Metabolism, 2017, 313, E284-E291.	3.5	13
259	Effects of Smoking Versus Nonsmoking on Postprandial Glucose Metabolism in Heavy Smokers Compared With Nonsmokers. Diabetes Care, 2018, 41, 1260-1267.	8.6	13
260	The efficacy and safety of exenatide once weekly in patients with type 2 diabetes. Expert Opinion on Pharmacotherapy, 2019, 20, 501-510.	1.8	13
261	Glycemic, maternal and neonatal outcomes in women with type 1 diabetes using continuous glucose monitoring during pregnancy â€“ Pump vs multiple daily injections, a secondary analysis of an observational cohort study. Acta Obstetricia Et Gynecologica Scandinavica, 2021, 100, 927-933.	2.8	13
262	Review: DPP IV inhibitors - current evidence and future directions. British Journal of Diabetes and Vascular Disease, 2007, 7, 69-74.	0.6	12
263	The unobtainable placebo: control of independent clinical research by industry?. Lancet, The, 2012, 379, 30.	13.7	12
264	Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study. BMJ Open, 2015, 5, e007791-e007791.	1.9	12
265	Higher Endogenous Glucose Production During OGTT vs Isoglycemic Intravenous Glucose Infusion. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4377-4384.	3.6	12
266	Model-Based Prediction of Plasma Concentration and Enterohepatic Circulation of Total Bile Acids in Humans. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 603-612.	2.5	12
267	Glucose-Dependent Insulinotropic Polypeptide Is a Pancreatic Polypeptide Secretagogue in Humans. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e502-e510.	3.6	12
268	Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes. Journal of the Endocrine Society, 2020, 4, bvaa097.	0.2	12
269	Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls. European Journal of Endocrinology, 2021, 185, 343-353.	3.7	12
270	Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2010, 3, 155-63.	2.4	12

#	Article	IF	Citations
271	Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study. BMJ Open, 2013, 3, e002764.	1.9	11
272	Retinal vascular and structural dynamics during acute hyperglycaemia. Acta Ophthalmologica, 2015, 93, 697-705.	1.1	11
273	Pancreatic Amylase and Lipase Plasma Concentrations Are Unaffected by Increments in Endogenous GLP-1 Levels Following Liquid Meal Tests. Diabetes Care, 2015, 38, e71-e72.	8.6	11
274	Postprandial incretin and islet hormone responses and dipeptidyl-peptidase 4 enzymatic activity in patients with maturity onset diabetes of the young. European Journal of Endocrinology, 2015, 173, 205-215.	3.7	11
275	Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density. Frontiers in Psychiatry, 2018, 9, 781.	2.6	11
276	Gluco-Metabolic Effects of Pharmacotherapy-Induced Modulation of Bile Acid Physiology. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 362-373.	3.6	11
277	The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition. Diabetes, 2020, 69, 2619-2629.	0.6	11
278	The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial. Diabetologia, 2020, 63, 1285-1298.	6.3	11
279	Glycemic Control and Variability of Diabetes Secondary to Total Pancreatectomy Assessed by Continuous Glucose Monitoring. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 168-173.	3.6	11
280	Use of exenatide and liraglutide in Denmark: a drug utilization study. European Journal of Clinical Pharmacology, 2014, 70, 205-214.	1.9	10
281	Sevelamer in a diabetologist's perspective: a phosphateâ€binding resin with glucoseâ€lowering potential. Diabetes, Obesity and Metabolism, 2015, 17, 116-120.	4.4	10
282	Shortâ€acting glucagonâ€like peptideâ€1 receptor agonists as addâ€on to insulin therapy in type 1 diabetes: <scp>A</scp> review. Diabetes, Obesity and Metabolism, 2017, 19, 915-925.	4.4	10
283	The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial. BMJ Open, 2017, 7, e014728.	1.9	10
284	The Gut: A Key to the Pathogenesis of Type 2 Diabetes?. Metabolic Syndrome and Related Disorders, 2017, 15, 259-262.	1.3	10
285	Comparing olive oil and C4-dietary oil, a prodrug for the GPR119 agonist, 2-oleoyl glycerol, less energy intake of the latter is needed to stimulate incretin hormone secretion in overweight subjects with type 2 diabetes. Nutrition and Diabetes, 2018, 8, 2.	3.2	10
286	Management of people with Type 2 diabetes shared between a specialized outpatient clinic and primary health care is noninferior to management in a specialized outpatient clinic: a randomized, noninferiority trial. Diabetic Medicine, 2019, 36, 854-861.	2.3	10
287	Experience of family function, family involvement, and selfâ€management in adult patients with type 2 diabetes: A thematic analysis. Journal of Advanced Nursing, 2020, 76, 621-631.	3.3	10
288	Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial. Trials, 2020, 21, 513.	1.6	10

#	Article	IF	Citations
289	Clinical pharmacology of imeglimin for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy, 2020, 21, 871-882.	1.8	10
290	INPP4B protects from metabolicÂsyndrome and associated disorders. Communications Biology, 2021, 4, 416.	4.4	10
291	Expression of Cholecystokinin and its Receptors in the Intestinal Tract of Type 2 Diabetes Patients and Healthy Controls. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2164-2170.	3.6	10
292	Myocardial Impairment and AcuteÂRespiratory Distress Syndrome inÂHospitalized Patients With COVID-19. JACC: Cardiovascular Imaging, 2020, 13, 2474-2476.	5.3	10
293	64-OR: Postprandial Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide in Type 2 Diabetes. Diabetes, 2019, 68, .	0.6	10
294	Beta-Hydroxybutyrate Suppresses Hepatic Production of the Ghrelin Receptor Antagonist LEAP2. Endocrinology, 2022, 163, .	2.8	10
295	The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial. BMJ Open, 2013, 3, e003834.	1.9	9
296	Recovery of the Incretin Effect in Type 2 Diabetic Patients After Biliopancreatic Diversion. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1984-1988.	3.6	9
297	Preclinical discovery and development of colesevelam for the treatment of type 2 diabetes. Expert Opinion on Drug Discovery, 2018, 13, 1161-1167.	5.0	9
298	Extrapancreatic glucagon: Present status. Diabetes Research and Clinical Practice, 2019, 147, 19-28.	2.8	9
299	The Glycemic Effect of Liraglutide Evaluated by Continuous Glucose Monitoring in Persons with Type 2 Diabetes Receiving Dialysis. Nephron, 2021, 145, 27-34.	1.8	9
300	Parenteral nutrition impairs plasma bile acid and gut hormone responses to mixed meal testing in lean healthy men. Clinical Nutrition, 2021, 40, 1013-1021.	5.0	9
301	Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1 Diabetes, and Healthy Control Subjects. Diabetes, 2021, 70, 1347-1356.	0.6	9
302	Study protocol for a multicentre, randomised, parallel group, sham-controlled clinical trial investigating the effect of transcutaneous vagal nerve stimulation on gastrointestinal symptoms in people with diabetes complicated with diabetic autonomic neuropathy: the DAN-VNS Study. BMJ Open, 2021, 11, e038677.	1.9	9
303	Therapy for Obesity Based on Gastrointestinal Hormones. Review of Diabetic Studies, 2011, 8, 339-347.	1.3	9
304	Increased Postprandial Response of Glucagon-Like Peptide-2 in Patients with Chronic Pancreatitis and Pancreatic Exocrine Insufficiency. Pancreatology, 2010, 10, 201-207.	1.1	8
305	Postprandial prolactin suppression appears absent in antipsychotic-treated male patients. Psychoneuroendocrinology, 2015, 60, 1-6.	2.7	8
306	Mathematical Modelling of Glucoseâ€Dependent Insulinotropic Polypeptide and Glucagonâ€like Peptideâ€1 following Ingestion of Glucose. Basic and Clinical Pharmacology and Toxicology, 2017, 121, 290-297.	2.5	8

#	Article	IF	Citations
307	GIP(3-30)NH2 â€“ a tool for the study of GIP physiology. Current Opinion in Pharmacology, 2020, 55, 31-40.	3.5	8
308	Glucagon-Like Peptide 2 Inhibits Postprandial Gallbladder Emptying in Man: A Randomized, Double-Blinded, Crossover Study. Clinical and Translational Gastroenterology, 2020, 11, e00257.	2.5	8
309	Incretin hormones and beta cell function in chronic pancreatitis. Danish Medical Bulletin, 2010, 57, B4163.	0.3	8
310	The effect of curcumin on hepatic fat content in individuals with obesity. Diabetes, Obesity and Metabolism, 2022, 24, 2192-2202.	4.4	8
311	Effect of bile acid sequestrants on glycaemic control: protocol for a systematic review with meta-analysis of randomised controlled trials. BMJ Open, 2012, 2, e001803.	1.9	7
312	Shared care management of patients with type 2 diabetes across the primary and secondary healthcare sectors: study protocol for a randomised controlled trial. Trials, 2016, 17, 277.	1.6	7
313	Gastrin secretion in normal subjects and diabetes patients is inhibited by glucagon-like peptide 1: a role in the gastric side effects of GLP-1-derived drugs?. Scandinavian Journal of Gastroenterology, 2019, 54, 1448-1451.	1.5	7
314	Gut Mucosal Gene Expression and Metabolic Changes After Rouxâ€enâ€Y Gastric Bypass Surgery. Obesity, 2020, 28, 2163-2174.	3.0	7
315	Vitamin D Supplementation Improves Fasting Insulin Levels and HDL Cholesterol in Infertile Men. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 98-108.	3.6	7
316	Gluco-metabolic effects of oral and intravenous alcohol administration in men. Endocrine Connections, 2019, 8, 1372-1382.	1.9	7
317	The use of double-balloon enteroscopy in retrieving mucosal biopsies from the entire human gastrointestinal tract. Scandinavian Journal of Gastroenterology, 2014, 49, 1143-1149.	1.5	6
318	Plasma YKL-40 during pregnancy and gestational diabetes mellitus. Journal of Reproductive Immunology, 2015, 112, 68-72.	1.9	6
319	Vagotomy and subsequent development of diabetes â€“ A nested caseâ€“control study. Metabolism: Clinical and Experimental, 2016, 65, 954-960.	3.4	6
320	Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trial. BMJ Open, 2018, 8, e022517.	1.9	6
321	Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan. Trials, 2020, 21, 867.	1.6	6
322	What is on the horizon for type 2 diabetes pharmacotherapy? â€“ An overview of the antidiabetic drug development pipeline. Expert Opinion on Drug Discovery, 2020, 15, 1253-1265.	5.0	6
323	Predictors of Improvement in Quality of Life When Treating Hypothyroidism. Journal of Thyroid Research, 2021, 2021, 1-7.	1.3	6
324	Bile acidâ€“farnesoid X receptorâ€“fibroblast growth factor 19 axis in patients with short bowel syndrome: The randomized, glepaglutide phase 2 trial. Journal of Parenteral and Enteral Nutrition, 2022, 46, 923-935.	2.6	6

#	Article	IF	Citations
325	Secretion of parathyroid hormone may be coupled to insulin secretion in humans. Endocrine Connections, 2020, 9, 747-754.	1.9	6
326	Glucagon Clearance Is Preserved in Type 2 Diabetes. Diabetes, 2022, 71, 73-82.	0.6	6
327	Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility. IDrugs: the Investigational Drugs Journal, 2008, 11, 497-501.	0.7	6
328	Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. Diabetes Care, 2022, 45, 1476-1481.	8.6	6
329	The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist. Expert Review of Endocrinology and Metabolism, 2011, 6, 513-525.	2.4	5
330	Comment on Xu et al. Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients With Type 2 Diabetes. Diabetes Care 2015;38:1858â€“1867. Diabetes Care, 2015, 38, e215-e215.	8.6	5
331	Postprandial Plasma Concentrations of ProANP in Patients with Type 2 Diabetes and Healthy Controls. Clinical Chemistry, 2017, 63, 1040-1041.	3.2	5
332	Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes. Frontiers in Endocrinology, 2019, 10, 242.	3.5	5
333	Treatment of type 2 diabetes in children: what are the specific considerations?. Expert Opinion on Pharmacotherapy, 2021, 22, 1-15.	1.8	5
334	Effects of shortâ€acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 221-227.	4.4	5
335	Enterohepatic, Gluco-metabolic, and Gut Microbial Characterization of Individuals With Bile Acid Malabsorption. , 2022, 1, 299-312.		5
336	Acute concomitant glucoseâ€dependent insulinotropic polypeptide receptor antagonism during glucagonâ€like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity. Diabetes, Obesity and Metabolism, 2022, 24, 1882-1887.	4.4	5
337	Delayed Ischemic Cecal Perforation Despite Optimal Decompression After Placement of a Self-Expanding Metal Stent: Report of a Case. Diseases of the Colon and Rectum, 2004, 47, 1970-1973.	1.3	4
338	TASK-1 potassium channel mutations in atrial fibrillation. European Heart Journal, 2013, 34, 3411-3411.	2.2	4
339	The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials. BMJ Open, 2014, 4, e005378-e005378.	1.9	4
340	Duodenal L cell density correlates with features of metabolic syndrome and plasma metabolites. Endocrine Connections, 2018, 7, 673-680.	1.9	4
341	No changes in levels of bone formation and resorption markers following a broad-spectrum antibiotic course. BMC Endocrine Disorders, 2018, 18, 60.	2.2	4
342	Effect of liraglutide on body weight and pain in patients with overweight and knee osteoarthritis: protocol for a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial. BMJ Open, 2019, 9, e024065.	1.9	4

#	Article	IF	Citations
343	The effect of acute intragastric vs. intravenous alcohol administration on inflammation markers, blood lipids and gallbladder motility in healthy men. Alcohol, 2020, 87, 29-37.	1.7	4
344	Prototype of an evidenceâ€based tool to aid individualized treatment for type 2 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 1666-1671.	4.4	4
345	Systemic Corticosteroids and the Risk of Venous Thromboembolism in Patients with Severe COPD: A Nationwide Study of 30,473 Outpatients. Biomedicines, 2021, 9, 874.	3.2	4
346	The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial. Diabetologia, 2021, 64, 2425-2431.	6.3	4
347	Glucoseâ€dependent insulinotropic polypeptide induces lipolysis during stable basal insulin substitution and hyperglycaemia in men with type 1 diabetes: A randomized, doubleâ€blind, placeboâ€controlled, crossover clinical trial. Diabetes, Obesity and Metabolism, 2022, 24, 142-147.	4.4	4
348	Mono- and Co-Activation of the GIP and GLP-1 Receptors Inhibits Bone Resorption. Diabetes, 2018, 67, .	0.6	4
349	10-LB: Dasiglucagon Ameliorates Postprandial Hypoglycemia after Roux-en-y Gastric Bypass. Diabetes, 2020, 69, 10-LB.	0.6	4
350	1662-P: Lower Expression of Bile Acid Transporters and Fibroblast Growth Factor 19 in Mucosa Biopsies from the Ileocecal Region in Persons with Type 2 Diabetes Compared with Healthy Controls. Diabetes, 2020, 69, .	0.6	4
351	Hemoglobin A1c and Fructosamine Evaluated in Patients with Type 2 Diabetes Receiving Peritoneal Dialysis Using Long-Term Continuous Glucose Monitoring. Nephron, 2022, 146, 146-152.	1.8	4
352	THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin â€“ physiology and pharmacology. European Journal of Endocrinology, 2022, 186, R93-R111.	3.7	4
353	Hypoglycaemia and rebound hyperglycaemia increase left ventricular systolic function in patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 2027-2037.	4.4	4
354	Comment on: Villareal et al. (2009) TCF7L2 Variant rs7903146 Affects the Risk of Type 2 Diabetes by Modulating Incretin Action. Diabetes;59:479â€“485. Diabetes, 2010, 59, e4-e4.	0.6	3
355	Electroretinography in healthy subjects in relation to systemic glucocorticoid intake. Documenta Ophthalmologica, 2012, 124, 49-57.	2.2	3
356	Dulaglutide: a novel once-weekly glucagon-like peptide-1 receptor agonist. Clinical Investigation, 2014, 4, 729-743.	0.0	3
357	Premature explantation of an EndoBarrier gastrointestinal liner because of sleeve invagination. Endoscopy, 2015, 47, E275-E276.	1.8	3
358	Disturbed postprandial glucose metabolism and gut hormone responses in non-diabetic patients with psoriasis. British Journal of Dermatology, 2016, 175, 1085-1088.	1.5	3
359	Is glucagonâ€like peptideâ€1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?. Diabetes, Obesity and Metabolism, 2018, 20, 1937-1943.	4.4	3
360	Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial. BMJ Open, 2018, 8, e021861.	1.9	3

#	Article	IF	Citations
361	Clinical characteristics and glucoseâ€lowering drug utilization among patients initiating liraglutide in Denmark: a routine clinical care prescription study. Journal of Diabetes, 2019, 11, 690-694.	1.8	3
362	Changes in oxidative nucleic acid modifications and inflammation following one-week treatment with the bile acid sequestrant sevelamer: Two randomised, placebo-controlled trials. Journal of Diabetes and Its Complications, 2020, 34, 107446.	2.3	3
363	Effect of the Incretin Hormones on the Endocrine Pancreas in End-Stage Renal Disease. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e564-e574.	3.6	3
364	Effect of shortâ€acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized doubleâ€blind placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2020, 22, 1639-1647.	4.4	3
365	Protocol for a randomised, double-blinded, placebo-controlled, double-dummy 6-week clinical trial comparing the treatment effects of the glucagon-like peptide 1 receptor agonist liraglutide versus the bile acid sequestrant colesevelam on bile acid malabsorption. BMJ Open, 2021, 11, e044711.	1.9	3
366	Weight gain on antipsychotics â€“ A perfect storm of complex pathophysiology and psychopharmacology. Acta Psychiatrica Scandinavica, 2021, 144, 521-523.	4.5	3
367	Prevalence of non-alcoholic fatty liver disease in patients with chronic kidney disease: a cross-sectional study. Nephrology Dialysis Transplantation, 2022, 37, 1927-1934.	0.7	3
368	A role for exogenous GLP-1 in the management of postprandial hypoglycaemia after Roux-en-Y gastric bypass?. European Journal of Endocrinology, 2019, 181, C5-C8.	3.7	3
369	Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 0, , 155.	2.4	3
370	Postprandial Effects of Individual and Combined GIP and GLP-1 Receptor Antagonization in Healthy Subjects. Diabetes, 2018, 67, 145-OR.	0.6	3
371	1952-P: Glucagon Receptor Antagonism Increases Plasma Amino Acids and Glucagon. Diabetes, 2019, 68, .	0.6	3
372	89-LB: The Effect of GIP on Plasma Glucose in a Setting of Prandial Insulin Overdose and Physical Activity after Meal Intake in Patients with Type 1 Diabetes. Diabetes, 2020, 69, .	0.6	3
373	Individual and Combined Glucose-Lowering Effects of Glucagon Receptor Antagonism and Dipeptidyl Peptidase-4 Inhibition. Diabetes, 2018, 67, .	0.6	3
374	Management of Patients with Type 2 Diabetes Shared between a Specialized Outpatient Clinic and General Practice Was Noninferior to Mono Management in a Specialized Outpatient Clinicâ€"A Prospective, Randomized, Noninferiority Trial. Diabetes, 2018, 67, .	0.6	3
375	1052-P: Investigation of the Extrapancreatic Effects of the DPP-4 Inhibitor Sitagliptin: A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial in Totally Pancreatectomized Patients. Diabetes, 2020, 69, .	0.6	3
376	The glucagon receptor antagonist LY2409021 has no effect on postprandial glucose in type 2 diabetes. European Journal of Endocrinology, 2022, 186, 207-221.	3.7	3
377	MYC mRNA expression throughout the intestine is not associated with body mass index or type 2 diabetes. Endocrinology, Diabetes and Metabolism, 2022, 5, e00327.	2.4	3
378	Acute changes in plasma glucose increases left ventricular systolic function in insulinâ€treated patients with type 2 diabetes and controls. Diabetes, Obesity and Metabolism, 2022, 24, 1123-1131.	4.4	3

#	Article	IF	Citations
379	Response to Comment on: Knop et al. (2007) Reduced Incretin Effect in Type 2 Diabetes: Cause or Consequence of the Diabetic State? Diabetes 56:1951 1959. Diabetes, 2008, 57, e2-e3.	0.6	2
380	Comment on: Chen et al. Utilizing the Second-Meal Effect in Type 2 Diabetes: Practical Use of a Soya-Yogurt Snack. Diabetes Care 2010;33:2552-2554. Diabetes Care, 2011, 34, e44-e44.	8.6	2
381	Glucagon and the gut hormones GLP-1 and oxyntomodulin increase resting energy expenditure in man. Regulatory Peptides, 2012, 177, S15-S16.	1.9	2
382	A 25-Year-Old Woman with Type 2 Diabetes and Liver Disease. Case Reports in Gastroenterology, 2014, 8, 398-403.	0.6	2
383	On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetes. Endocrine Connections, 2014, 3, 193-199.	1.9	2
384	SU18. GLP-1 Receptor Agonist Treatment in Schizophrenia Patients With Obesity. Schizophrenia Bulletin, 2017, 43, S167-S167.	4.3	2
385	Human myotubularin-related protein 9 regulates ER-to-Golgi trafficking and modulates WNT3A secretion. Experimental Cell Research, 2020, 386, 111709.	2.6	2
386	Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes. Nutrients, 2020, 12, 2928.	4.1	2
387	Metabolic effects of 1-week binge drinking and fast food intake during Roskilde Festival in young healthy male adults. European Journal of Endocrinology, 2021, 185, 23-32.	3.7	2
388	Neurotensin secretion after Rouxâ€•nâ€Y gastric bypass, sleeve gastrectomy, and truncal vagotomy with pyloroplasty. Neurogastroenterology and Motility, 2021, , e14210.	3.0	2
389	Individual and Combined Glucose-Lowering Effects of Glucagon Receptor Antagonism and Sodium-Glucose Cotransporter 2 Inhibition. Diabetes, 2018, 67, 1942-P.	0.6	2
390	1145-P: Acarbose-Induced Glucagon-Like Peptide-1 Secretion Contributes to the Glucose-Lowering Effect of Acarbose. Diabetes, 2019, 68, 1145-P.	0.6	2
391	A gut feeling about glucagon. Endocrine Abstracts, 0, , .	0.0	2
392	1140-P: Empagliflozin Attenuates Fasting and Postprandial Hyperglycemia in Totally Pancreatectomized Patients: A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial. Diabetes, 2020, 69, .	0.6	2
393	No detectable effect of a type 2 diabetes-associated TCF7L2 genotype on the incretin effect. Endocrine Connections, 2020, 9, 1221-1232.	1.9	2
394	Editorial: Proglucagon-Derived Peptides. Frontiers in Endocrinology, 2021, 12, 776871.	3.5	2
395	First Case Report Associating Chronic Pancreatitis and Ehlers-Danlos Syndrome. Pancreas, 2011, 40, 157-159.	1.1	1
396	Comment on: Gogebakan et al. Glucose-Dependent Insulinotropic Polypeptide Reduces Fat-Specific Expression and Activity of 11Â-Hydroxysteroid Dehydrogenase Type 1 and Inhibits Release of Free Fatty Acids. Diabetes 2012;61:292-300. Diabetes, 2012, 61, e12-e12.	0.6	1

#	Article	IF	Citations
397	Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report. BMC Research Notes, 2014, 7, 326.	1.4	1
398	Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide. Expert Review of Clinical Pharmacology, 2015, 8, 273-282.	3.1	1
399	Effects of glucose-dependent insulinotropic polypeptide on glucagon. Cardiovascular Endocrinology, 2016, 5, 75-81.	0.8	1
400	Liraglutide â€" preventing or postponing T2DM diagnosis?. Nature Reviews Endocrinology, 2017, 13, 320-322.	9.6	1
401	OP0340â€…Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal observational studies. , 2017, , .		1
402	Restoration of enteroendocrine and pancreatic function after internal hernia and short bowel syndrome in a young woman with gastric bypass - a 2-year follow-up. Physiological Reports, 2018, 6, e13686.	1.7	1
403	O12.4. EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST EXENATIDE ON BONE STATUS IN OBESE, NON-DIABETIC, ANTIPSYCHOTIC-TREATED SCHIZOPHRENIA SPECTRUM PATIENTS. Schizophrenia Bulletin, 2019, 45, S198-S199.	4.3	1
404	Normal insulin sensitivity, glucose tolerance, gut incretin and pancreatic hormone responses in adults with atopic dermatitis. Diabetes, Obesity and Metabolism, 2020, 22, 2161-2169.	4.4	1
405	Reduced erythrocyte lifespan measured by chromiumâ€51 in patients with typeâ€‰2 diabetes undergoing longâ€term hemodialysis. Hemodialysis International, 2021, 25, 198-204.	0.9	1
406	Pancreatic polypeptide: A potential biomarker of glucoseâ€dependent insulinotropic polypeptide receptor activation in vivo. Diabetic Medicine, 2021, 38, e14592.	2.3	1
407	Positioning Glucagon-like-peptide- 1 - based Treatments within an Optimal Management Regimen for Type 2 Diabetes. European Endocrinology, 2008, 4, 44.	1.5	1
408	Glucagon Resistance at the Level of Amino Acid Turnover and Ureagenesis in Obese Subjects with Hepatic Steatosis. Diabetes, 2018, 67, 147-OR.	0.6	1
409	1976-P: Physiological Effects of GIP(1-30)NH2 in Healthy Subjects. Diabetes, 2019, 68, 1976-P.	0.6	1
410	981-P: GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in HNF1A Diabetes. Diabetes, 2019, 68, .	0.6	1
411	GLP-1 Receptor Agonists and DPP-4 Inhibitors. MD Conference Express, 2012, 12, 24-26.	0.0	1
412	Clinical Features and Hepatic Molecular Characteristics in NAFLD and NASH Patients Compared to Normal Weight Healthy Individuals. Diabetes, 2018, 67, .	0.6	1
413	351-OR: Six-Day Subcutaneous GIP Infusion Increases Glycemic Time-in-Range in Patients with Type 1 Diabetes. Diabetes, 2020, 69, 351-OR.	0.6	1
414	The impact of pancreatic enzyme supplementation on postprandial responses of glucagon-like Peptide-2 in patients with chronic pancreatitis and pancreatic exocrine insufficiency. JOP: Journal of the Pancreas, 2010, 11, 489-91.	1.5	1

#	Article	IF	Citations
415	Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in Beta Cell Function in Patients with Type 2 Diabetes. Diabetes, 0, , .	0.6	1
416	25th Scientific Meeting of the Angloâ€"Danishâ€"Dutch Diabetes Group. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2008, 25, 17-17.	0.2	0
417	Add-on to metformin in T2DMâ€"linagliptin or glimepiride?. Nature Reviews Endocrinology, 2012, 8, 576-578.	9.6	0
418	Letter by Knop Regarding Article, â€œEffect of Torcetrapib on Glucose, Insulin, and Hemoglobin A 1c in Subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trialâ€• Circulation, 2012, 125, e428.	1.6	0
419	Authors' reply to de Oliveira and Iverson. BMJ: British Medical Journal, 2012, 344, e1459-e1459.	2.3	0
420	Acute dipeptidyl peptidase 4 inhibition has no impact on the incretin effect, glucose tolerance or gastric emptying in healthy subjects. Regulatory Peptides, 2012, 177, S30-S31.	1.9	0
421	The Role of Glucagon-like Receptor-1 Agonists in the Metabolic Syndrome. , 2013, , 165-183.		0
422	Cardiovascular effects of alpha-linolenic acid â€" a possible role of glucagon-like peptide-1. Experimental Biology and Medicine, 2013, 238, 1116-1117.	2.4	0
423	The Authors Reply:. Kidney International, 2014, 85, 212-213.	5.2	0
424	Poster #S8 GLUCOMETABOLIC HORMONES AND CARDIOVASCULAR RISK MARKERS IN ANTIPSYCHOTIC-TREATED PATIENTS. Schizophrenia Research, 2014, 153, S90-S91.	2.0	0
425	Response to the Letter: â€œEpidemiologic Association Between Antibiotic Use With the Risk of Developing Type 2 Diabetesâ€•by LÃ³pez-HernÃ¡ndez, D.. Journal of Clinical Endocrinology and Metabolism, 2015, 100, L121-L121.	3.6	0
426	â€˜No cognitiveâ€•enhancing effect of <scp>GLP</scp>â€•1 receptor agonism in antipsychoticâ€•treated, obese patients with schizophreniaâ€™: authors' response. Acta Psychiatrica Scandinavica, 2017, 136, 526-527.	4.5	0
427	MO019INCRETIN EFFECT IS REDUCED IN END-STAGE RENAL DISEASE. Nephrology Dialysis Transplantation, 2017, 32, iii49-iii49.	0.7	0
428	Response to Letter to the Editor: â€œHemodynamic Effects of Glucagon: A Literature Reviewâ€• Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4480-4481.	3.6	0
429	SP426HYPOGLYCAEMIC EPISODES EVALUATED BY CONTINUOUS GLUCOSE MONITORING IN PATIENTS WITH TYPE 2 DIABETES AND DIALYSIS-DEPENDENT END-STAGE RENAL DISEASE RANDOMISED TO 12-WEEK LIRAGLUTIDE OR PLACEBO TREATMENT. Nephrology Dialysis Transplantation, 2018, 33, i492-i492.	0.7	0
430	Glucose metabolism in patients with psoriasis. British Journal of Dermatology, 2019, 180, e41-e41.	1.5	0
431	OP0011â€…EFFECT OF LIRAGLUTIDE ON BODY WEIGHT AND PAIN IN THE TREATMENT OF OVERWEIGHT AND KNEE OSTEOARTHRITIS: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY. , 2019, , .		0
432	FRI-339-Clinical translatability of a diet-induced obese mouse model of non-alcoholic steatohepatitis. Journal of Hepatology, 2019, 70, e544.	3.7	0

#	Article	IF	Citations
433	Response to Letter to the Editor from McKee and McGill: â€œGlycemic Control and Variability of Diabetes Secondary to Total Pancreatectomy Assessed by Continuous Glucose Monitoringâ€. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4307-e4308.	3.6	0
434	MO633GLYCAEMIC MARKERS IN PATIENTS WITH TYPE 2 DIABETES UNDERGOING HAEMODIALYSIS EVALUATED BY LONG-TERM CONTINUOUS GLUCOSE MONITORING*. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
435	MO457PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A CASE-CONTROL STUDY. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
436	Mechanisms in Endocrinology: The physiology of neuronostatin. European Journal of Endocrinology, 2021, 185, R93-R101.	3.7	0
437	The Accuracy of Hemoglobin A1c and Fructosamine Evaluated by Long-Term Continuous Glucose Monitoring in Patients with Type 2 Diabetes Undergoing Hemodialysis. Blood Purification, 2021, , 1-9.	1.8	0
438	Glucagon-like Peptides and Insulin Sensitivity. , 2008, , 233-254.		0
439	The Effect of Ethanol on Inflammation Markers and FGF-21 in Healthy Individuals. Diabetes, 2018, 67, .	0.6	0
440	More Subjects Achieved Composite Reductions of =1% HbA1c, =5% Body Weight, and =5 mmHg SBP with Semaglutide vs. Comparators (SUSTAIN 1-5, 7). Diabetes, 2018, 67, .	0.6	0
441	Glucagon-Like Peptide-1 Is a Significant Determinant of the Second-Meal Effect in Patients with Type 2 Diabetes. Diabetes, 2018, 67, 1963-P.	0.6	0
442	The Role of Glucagon-Like Peptide-1 for the Postprandial Effects of Metformin in Type 2 Diabetes. Diabetes, 2018, 67, .	0.6	0
443	1980-P: A Characterization of Postprandial Glucose Metabolism and Incretin Hormone Responses in Patients with Bile Acid Malabsorption. Diabetes, 2019, 68, 1980-P.	0.6	0
444	1186-P: Lean Women with Polycystic Ovary Syndrome and Insulin Resistance Have Normal Incretin Effect, which Is Unaffected by Metformin Therapy. Diabetes, 2019, 68, 1186-P.	0.6	0
445	62-OR: Evidence of Gut-Derived Glucagon in Man. Diabetes, 2019, 68, .	0.6	0
446	63-OR: The Physiological Effects of Extrapancreatic Glucagon in Totally Pancreatectomized Patients Evaluated Using Glucagon Receptor Antagonism. Diabetes, 2019, 68, 63-OR.	0.6	0
447	1721-P: Effect of the TCF7L2 Variant rs7903146 T Allele on the Incretin Effect in Individuals with Normal Glucose Tolerance or Type 2 Diabetes. Diabetes, 2019, 68, .	0.6	0
448	23-OR: The Effect of 14-Day Atorvastatin Treatment on Postprandial Glucose Metabolism in Healthy Malesâ€"A Link to Why Statin Therapy Increases the Risk of Type 2 Diabetes?. Diabetes, 2019, 68, .	0.6	0
449	1982-P: Glucagon-Like Peptide-2 Inhibits Postprandial Gallbladder Emptying in Healthy Male Individualsâ€"A Randomized, Double-Blinded, Placebo-Controlled Study. Diabetes, 2019, 68, 1982-P.	0.6	0
450	2187-PUB: Identifying Risk Predictors for Gastrointestinal Adverse Events with Once-Weekly Semaglutide. Diabetes, 2020, 69, 2187-PUB.	0.6	0

#	Article	IF	Citations
451	1906-P: Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients with Type 2 Diabetes. Diabetes, 2020, 69, 1906-P.	0.6	0
452	160-OR: Acute Changes in Plasma Glucose Have Impact on Left Ventricular Systolic Function in Insulin-Treated Patients with Type 2 Diabetes. Diabetes, 2020, 69, 160-OR.	0.6	0
453	263-OR: Counterregulatory Responses to Hypoglycemia in Totally Pancreatectomized Patients. Diabetes, 2020, 69, 263-OR.	0.6	0
454	923-P: Improved Glycemic Variability and Control without Increased Risk of Hypoglycemia when Linagliptin Is Added to Glimepiride Therapy in Patients with HNF1A-Diabetes. Diabetes, 2020, 69, .	0.6	0
455	2160-PUB: Development of an Evidence-Based Tool to Facilitate Individualized Treatment in the Clinic for Patients with Type 2 Diabetes. Diabetes, 2020, 69, 2160-PUB.	0.6	0
456	1905-P: Downregulation of HMGCS2 Expression in Small Intestinal Mucosa Biopsies after Roux-en-Y Gastric Bypass Surgery: A Possible Contributor to GLP-1 Hypersecretion?. Diabetes, 2020, 69, 1905-P.	0.6	0
457	2103-P: Glucose-Dependent Insulinotropic Polypeptide (GIP) Protects against Cytokine-Induced Cell Death and Exerts Both Insulinotropic and Glucagonotropic Effects in Human Islets. Diabetes, 2020, 69, .	0.6	0
458	1094-P: Short-Acting Exenatide and Markers of Cardiovascular Disease in Type 1 Diabetes: A Randomized, Double-Blinded, Placebo-Controlled Trial. Diabetes, 2020, 69, 1094-P.	0.6	0
459	Long-term use of inhaled corticosteroids and the risk of type 2 diabetes in COPD. , 2020, , .		0
460	Gastric Aspiration Improves Postprandial Glucose Tolerance Without Causing a Compensatory Increase in Appetite and Food Intake. Obesity Surgery, 2022, 32, 1385-1390.	2.1	0
461	MO408: Hepatic Steatosis in Patients With Type 2 Diabetes and Chronic Kidney Disease. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0